Related Experiment Video

Updated: Jan 5, 2026

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

494

Update on the management of colchicine resistant Familial Mediterranean Fever (FMF)

Georges El Hasbani1, Ali Jawad2, Imad Uthman3

  • 1Division of Rheumatology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.

Orphanet Journal of Rare Diseases
|October 17, 2019
PubMed
Abstract

Insights

Familial Mediterranean Fever (FMF) treatment challenges are addressed by biologics when colchicine fails. Combining biologics with colchicine offers a promising therapeutic strategy for FMF patients.

Area of Science:

  • Rheumatology
  • Immunology
  • Genetics

Background:

  • Familial Mediterranean Fever (FMF) is an autoinflammatory disease marked by recurrent inflammatory attacks.
  • Colchicine is the primary treatment, but resistance and intolerance affect patient outcomes.

Purpose of the Study:

  • To evaluate the efficacy of biologic therapies in FMF patients.
  • To explore alternative treatments for colchicine-resistant or intolerant FMF cases.

Main Methods:

  • Review of studies on biologic treatments for FMF.
  • Analysis of cytokine levels (TNF alpha, IL-1, IL-6) in FMF carriers and patients.

Main Results:

  • Biologic agents, including anti-IL-1, anti-IL-6, and TNF inhibitors, show success in treating FMF.
  • Elevated serum levels of TNF alpha, IL-1, and IL-6 are observed in FMF carriers.

Conclusions:

  • Biologics are effective for FMF patients unresponsive or intolerant to colchicine.
  • Combination therapy with colchicine and biologics is recommended for optimal FMF management.
Keywords:
Autoinflammatory diseasesBiologicsColchicine resistanceFamilial Mediterranean fever

More Related Videos

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients07:04

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Published on: February 11, 2017

20.0K
Generation and Long-term Maintenance of Nerve-free Hydra06:33

Generation and Long-term Maintenance of Nerve-free Hydra

Published on: July 7, 2017

12.9K

Related Concept Videos

Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
265
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.6K
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
149
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
257
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
426
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
409